Olga Martynova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olga Martynova has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Okhotin
St. Petersburg State University
9 shared publications - Ivan S. Stilidi
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Yaroslav A. Zhulikov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Екатерина Вадимовна Евдокимова
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - A. Yu. Kolycheva
N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
1 shared publication - Abidat K. Kachmasova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication
Latest Publications
- 24 September 2026
- Published by Elsevier in Theoretical Computer Science
- Vol. 1087
Exact descriptional complexity of determinization of input-driven pushdown automata
- 24 September 2026
- Published by Elsevier in Theoretical Computer Science
- Vol. 1087
Exact descriptional complexity of determinization of input-driven pushdown automata
- Open Access
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 35-44
Retrospective analysis of BUCEN score prognostic value in Russian population of patients with advanced adrenocortical carcinoma treated with platinum-based chemotherapy in combination with mitotane
Introduction. Currently, the algorithm for selecting first-line treatment for advanced adrenocortical carcinoma (ACC) is not clearly defined; the choice between mitotane monotherapy and its combination with platinum-based chemotherapy remains controversial. In a large retrospective study (n = 439), the BUCEN scoring system was proposed as a predictor of treatment response, which could help determine first-line therapy [9]. Our study aimed to evaluate the prognostic value of the BUCEN scores in the Russian population of patients with advanced ACC, treated with a combination of platinum-based chemotherapy and mitotane. Materials and Methods. This retrospective single-center study included patients aged ≥ 18 years with advanced ACC and pre-assessed BUCEN scores who received platinum-based chemotherapy in combination with mitotane at the N. N. Blokhin National Medical Research Center of Oncology between 2016 and 2025. Result. The study included 63 patients with BUCEN scores of 0–2 (n = 31; 49.2 %) and ≥ 3 (n = 32; 50.8 %). Fifty patients (79.4 %) received etoposide + cisplatin + doxorubicin (EDP), 5 patients (7.9 %) received etoposide + cisplatin (EP), and 8 (12.7 %) received etoposide + carboplatin (EC). Therapeutic serum levels of mitotane were achieved in 42 patients (66.7 %). The objective response rate (ORR), disease control rate (DCR) at ≥ 6 months, and DCR at ≥ 12 months were 20.6 %, 62.3 %, and 26.3 %, respectively. A BUCEN score of 0–2 was associated with an improved ORR (p = 0.03), a DCR at ≥ 6 months (p < 0.01), and a DCR at ≥ 12 months (p = 0.03). A multivariate analysis revealed that non-anthracycline regimens in patients with BUCEN ≥ 3 were associated with a statistically significant decrease in progression-free survival (PFS) and overall survival (OS). A statistically significant OS improvement was observed in patients with recurrence-free survival of ≥ 12 months post-adrenalectomy (p = 0.04). Conclusion. The BUCEN scoring system is reproducible, simple to use, and could be applied for the stratification of patients with advanced ACC. Implementation of this system in clinical practice to pre-select patients for mitotane monotherapy as a first-line treatment requires prospective validation. The significantly poorer outcomes in the EP / EC group may partly reflect patient characteristics, as these regimens were used in those with contraindications to anthracyclines or cisplatin. However, based on our data, we do not recommend non-anthracycline regimens in patients without contraindications to EDP chemotherapy.
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 35-44
Open AccessRetrospective analysis of BUCEN score prognostic value in Russian population of patients with advanced adrenocortical carcinoma treated with platinum-based chemotherapy in combination with mitotane
Introduction. Currently, the algorithm for selecting first-line treatment for advanced adrenocortical carcinoma (ACC) is not clearly defined; the choice between mitotane monotherapy and its combination with platinum-based chemotherapy remains controversial. In a large retrospective study (n = 439), the BUCEN scoring system was proposed as a predictor of treatment response, which could help determine first-line therapy [9]. Our study aimed to evaluate the prognostic value of the BUCEN scores in the Russian population of patients with advanced ACC, treated with a combination of platinum-based chemotherapy and mitotane. Materials and Methods. This retrospective single-center study included patients aged ≥ 18 years with advanced ACC and pre-assessed BUCEN scores who received platinum-based chemotherapy in combination with mitotane at the N. N. Blokhin National Medical Research Center of Oncology between 2016 and 2025. Result. The study included 63 patients with BUCEN scores of 0–2 (n = 31; 49.2 %) and ≥ 3 (n = 32; 50.8 %). Fifty patients (79.4 %) received etoposide + cisplatin + doxorubicin (EDP), 5 patients (7.9 %) received etoposide + cisplatin (EP), and 8 (12.7 %) received etoposide + carboplatin (EC). Therapeutic serum levels of mitotane were achieved in 42 patients (66.7 %). The objective response rate (ORR), disease control rate (DCR) at ≥ 6 months, and DCR at ≥ 12 months were 20.6 %, 62.3 %, and 26.3 %, respectively. A BUCEN score of 0–2 was associated with an improved ORR (p = 0.03), a DCR at ≥ 6 months (p < 0.01), and a DCR at ≥ 12 months (p = 0.03). A multivariate analysis revealed that non-anthracycline regimens in patients with BUCEN ≥ 3 were associated with a statistically significant decrease in progression-free survival (PFS) and overall survival (OS). A statistically significant OS improvement was observed in patients with recurrence-free survival of ≥ 12 months post-adrenalectomy (p = 0.04). Conclusion. The BUCEN scoring system is reproducible, simple to use, and could be applied for the stratification of patients with advanced ACC. Implementation of this system in clinical practice to pre-select patients for mitotane monotherapy as a first-line treatment requires prospective validation. The significantly poorer outcomes in the EP / EC group may partly reflect patient characteristics, as these regimens were used in those with contraindications to anthracyclines or cisplatin. However, based on our data, we do not recommend non-anthracycline regimens in patients without contraindications to EDP chemotherapy.
- 7 May 2026
- Published by Elsevier in Information and Computation
- Vol. 311
Improved bounds on the length of shortest strings accepted by two-way finite automata
- 7 May 2026
- Published by Elsevier in Information and Computation
- Vol. 311
Improved bounds on the length of shortest strings accepted by two-way finite automata
- Open Access
- 15 March 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (1)
Efficacy of mFOLFIRINOX chemotherapy for treatment of high-grade G3 neuroendocrine tumors and gastroenteropancreatic neuroendocrine carcinomas
Background. Gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC) are rare tumors. Despite the differences in genetic characteristics, treatment principles for GEP-NECs are extrapolated from lung NECs. A small retrospective study demonstrated potential effectiveness of the mFOLFIRINOX regimen. Aim. To evaluate the efficacy of mFOLFIRINOX ± somatostatin analogues in treatment of inoperable or metastatic G3 Ki-67 ≥55 % GEP-NECs and neuroendocrine tumors (NETs) in a prospective cohort. Materials and methods. A prospective single-center phase II trial with the Simon’s two-stage design was conducted. The primary endpoint was disease control (DC) ≥6 months. The statistical hypothesis was that the mFOLFIRINOX regimen would increase the disease control rate from 50 % (historical control) to 70 %. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). In the 1st stage, 16 patients were planned for enrollment. If ≥9 patients achieved DC ≥6 months, the cohort would be expanded to 39 patients. Inclusion criteria: patients ≥18 years with histologically confirmed G3 Ki-67 ≥55 % GEP-NEC or NET, ECOG performance status 0–2. Patient enrollment took place between 2019 to February of 2024. Results. Sixteen patients were included in the study (12 men, 4 women). The most common primary tumor sites were the stomach (8 patients, 50 %) and pancreas (5 patients, 31.3 %). Large-cell NEC was diagnosed in 10 patients (62.5 %), small-cell NEC in 1 patient (6.3 %), and G3 NET in 5 patients (31.3 %). Median Ki-67 index was 70 % (range 40–95 %). Stage IV disease was diagnosed in 15 patients (93.7 %), and 1 patient (6.3 %) had unresectable gastric NEC. The liver was the most frequent site of metastases (n = 11, 68.8 %), with isolated liver involvement in 9 patients (56.3 %). ECOG performance status was 0–1 in 15 patients (93.7 %). The majority (n = 14, 87.5 %) of patients received mFOLFIRINOX as 1st line treatment. Positive expression of somatostatin receptors SSTR2A / 5 was found in 7 patients (43.7 %), who additionally received somatostatin analogues. ORR was 62.5 % (n = 10), and stable disease was observed in 37.5 % (n = 6) of patients. Disease control ≥6 months was achieved in 93.7 % of patients (n = 15). With a median follow-up of 13.2 months, median PFS was 10.8 months (95 % confidence interval 7.57–14.1). One serious adverse event (myocardial infarction) was reported. No grade V toxicity was observed. Conclusion. mFOLFIRINOX chemotherapy demonstrated promising results in treatment of G3 Ki-67 ≥55 % GEP NECs and NETs. The primary endpoint was met, and the study is ongoing.
- 15 March 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (1)
Open AccessEfficacy of mFOLFIRINOX chemotherapy for treatment of high-grade G3 neuroendocrine tumors and gastroenteropancreatic neuroendocrine carcinomas
Background. Gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC) are rare tumors. Despite the differences in genetic characteristics, treatment principles for GEP-NECs are extrapolated from lung NECs. A small retrospective study demonstrated potential effectiveness of the mFOLFIRINOX regimen. Aim. To evaluate the efficacy of mFOLFIRINOX ± somatostatin analogues in treatment of inoperable or metastatic G3 Ki-67 ≥55 % GEP-NECs and neuroendocrine tumors (NETs) in a prospective cohort. Materials and methods. A prospective single-center phase II trial with the Simon’s two-stage design was conducted. The primary endpoint was disease control (DC) ≥6 months. The statistical hypothesis was that the mFOLFIRINOX regimen would increase the disease control rate from 50 % (historical control) to 70 %. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). In the 1st stage, 16 patients were planned for enrollment. If ≥9 patients achieved DC ≥6 months, the cohort would be expanded to 39 patients. Inclusion criteria: patients ≥18 years with histologically confirmed G3 Ki-67 ≥55 % GEP-NEC or NET, ECOG performance status 0–2. Patient enrollment took place between 2019 to February of 2024. Results. Sixteen patients were included in the study (12 men, 4 women). The most common primary tumor sites were the stomach (8 patients, 50 %) and pancreas (5 patients, 31.3 %). Large-cell NEC was diagnosed in 10 patients (62.5 %), small-cell NEC in 1 patient (6.3 %), and G3 NET in 5 patients (31.3 %). Median Ki-67 index was 70 % (range 40–95 %). Stage IV disease was diagnosed in 15 patients (93.7 %), and 1 patient (6.3 %) had unresectable gastric NEC. The liver was the most frequent site of metastases (n = 11, 68.8 %), with isolated liver involvement in 9 patients (56.3 %). ECOG performance status was 0–1 in 15 patients (93.7 %). The majority (n = 14, 87.5 %) of patients received mFOLFIRINOX as 1st line treatment. Positive expression of somatostatin receptors SSTR2A / 5 was found in 7 patients (43.7 %), who additionally received somatostatin analogues. ORR was 62.5 % (n = 10), and stable disease was observed in 37.5 % (n = 6) of patients. Disease control ≥6 months was achieved in 93.7 % of patients (n = 15). With a median follow-up of 13.2 months, median PFS was 10.8 months (95 % confidence interval 7.57–14.1). One serious adverse event (myocardial infarction) was reported. No grade V toxicity was observed. Conclusion. mFOLFIRINOX chemotherapy demonstrated promising results in treatment of G3 Ki-67 ≥55 % GEP NECs and NETs. The primary endpoint was met, and the study is ongoing.
- 25 January 2025
- Published by World Scientific Pub Co Pte Ltd in International Journal of Foundations of Computer Science
- Vol. 37 (01) , 23-46
A Time to Cast Away Stones: On a Family of Pebble Automata
Deterministic graph-walking automata equipped with finitely many “drop-once” pebbles are investigated: these automata explore a graph by following its edges using finitely many states, and they can also leave pebbles at some nodes, but cannot lift these pebbles anymore. It is proved that for every such automaton there is a graph-walking automaton without pebbles that recognizes the same set of graphs. To be precise, for an automaton with m drop-once pebbles and n states, operating on graphs with k labels of edge end-points, an automaton without pebbles with [ ] states accepting the same set of graphs is constructed. The results apply to two-way finite automata (with [ ]) and to tree-walking automata as special cases.
- 25 January 2025
- Published by World Scientific Pub Co Pte Ltd in International Journal of Foundations of Computer Science
- Vol. 37 (01) , 23-46
A Time to Cast Away Stones: On a Family of Pebble Automata
Deterministic graph-walking automata equipped with finitely many “drop-once” pebbles are investigated: these automata explore a graph by following its edges using finitely many states, and they can also leave pebbles at some nodes, but cannot lift these pebbles anymore. It is proved that for every such automaton there is a graph-walking automaton without pebbles that recognizes the same set of graphs. To be precise, for an automaton with m drop-once pebbles and n states, operating on graphs with k labels of edge end-points, an automaton without pebbles with [ ] states accepting the same set of graphs is constructed. The results apply to two-way finite automata (with [ ]) and to tree-walking automata as special cases.
- 3 September 2024
- Published by Springer Nature
- p. 249-260
Exact Descriptional Complexity of Determinization of Input-Driven Pushdown Automata
- 3 September 2024
- Published by Springer Nature
- p. 249-260
Exact Descriptional Complexity of Determinization of Input-Driven Pushdown Automata
- 12 July 2024
- Published by World Scientific Pub Co Pte Ltd in International Journal of Foundations of Computer Science
- Vol. 37 (06) , 1-21
State Complexity of Boolean Operations on Graph-Walking Automata
Finite automata that traverse graphs by moving along their edges are known as graph-walking automata (GWA). This paper investigates the state complexity of Boolean operations for this model. It is proved that the union of GWA with [ ] and [ ] states, with [ ], operating on graphs with [ ] labels of edge end-points, is representable by a GWA with [ ] states, and at least [ ] states are necessary in the worst case. For the intersection, the upper bound is [ ] and the lower bound is [ ]. The upper bound for the complementation is [ ], and the lower bound is [ ].
- 12 July 2024
- Published by World Scientific Pub Co Pte Ltd in International Journal of Foundations of Computer Science
- Vol. 37 (06) , 1-21
State Complexity of Boolean Operations on Graph-Walking Automata
Finite automata that traverse graphs by moving along their edges are known as graph-walking automata (GWA). This paper investigates the state complexity of Boolean operations for this model. It is proved that the union of GWA with [ ] and [ ] states, with [ ], operating on graphs with [ ] labels of edge end-points, is representable by a GWA with [ ] states, and at least [ ] states are necessary in the worst case. For the intersection, the upper bound is [ ] and the lower bound is [ ]. The upper bound for the complementation is [ ], and the lower bound is [ ].
- 30 November 2023
- Published by Elsevier in Information and Computation
- Vol. 296
Complexity of the emptiness problem for graph-walking automata and for tilings with star subgraphs
- 30 November 2023
- Published by Elsevier in Information and Computation
- Vol. 296
Complexity of the emptiness problem for graph-walking automata and for tilings with star subgraphs
- 17 September 2023
- Published by Elsevier in Theoretical Computer Science
- Vol. 979, 114197
Homomorphisms and inverse homomorphisms on graph-walking automata
- 17 September 2023
- Published by Elsevier in Theoretical Computer Science
- Vol. 979, 114197
Homomorphisms and inverse homomorphisms on graph-walking automata